BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6% - Here's What Happened
BioCryst Pharmaceuticals (NASDAQ:BCRX) saw its stock trade up 6% during midday trading on Monday, even with an 86% decline in session volume. The company recently reported a significant earnings beat, with EPS of $1.12 against an expected $0.07, and revenue up 209% year-over-year. Analysts maintain a "Moderate Buy" consensus rating with a target price of $19.64, though a recent insider sale of 150,000 shares was noted.
BioCryst names Sandeep Menon as chief R&D officer
BioCryst Pharmaceuticals has appointed Dr. Sandeep M. Menon as Chief Research and Development Officer. Dr. Menon previously served as Chief Development Officer at Alnylam Pharmaceuticals and held senior R&D leadership roles at Pfizer. This appointment follows BioCryst's strong financial momentum, with a 94% revenue surge and a 28% stock return over the last six months, and analysts predicting continued profitability.
BioCryst taps AMVUTTRA, PAXLOVID veteran to lead R&D effort
BioCryst Pharmaceuticals (Nasdaq: BCRX) has appointed Sandeep M. Menon, MD, PhD, as its new Chief Research and Development Officer, effective April 6, 2026. Menon brings extensive experience from Alnylam and Pfizer, having played a key role in the FDA approval of AMVUTTRA and the clinical development of PAXLOVID. This strategic hire aims to strengthen BioCryst's R&D strategy, specifically as its navenibart program advances towards a potential BLA and the company focuses on expanding its rare disease portfolio.
BioCryst Pharmaceuticals Appoints Dr. Sandeep M. Menon as Chief Research and Development Officer
BioCryst Pharmaceuticals has appointed Dr. Sandeep M. Menon as Chief Research and Development Officer to spearhead the advancement of rare disease therapies. Dr. Menon brings extensive experience from Alnylam Pharmaceuticals and Pfizer, where he led global clinical development and secured FDA approvals for significant therapies. His appointment is expected to bolster BioCryst's pipeline development, particularly the navenibart program, and strengthen its R&D strategy as the company focuses on expanding its therapeutic offerings for rare diseases.
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
BioCryst Pharmaceuticals, Inc. has appointed Sandeep M. Menon, MD, PhD, as its new Chief Research and Development Officer. Dr. Menon brings extensive experience from Alnylam Pharmaceuticals and Pfizer, where he led significant advancements in drug development and regulatory approvals. His appointment is expected to strengthen BioCryst's R&D strategy as the company enters a critical phase with its navenibart program and expands its focus on rare disease therapies.
Operating cash flow per share of BioCryst Pharmaceuticals, Inc. – DUS:BO1
This page provides financial information for BioCryst Pharmaceuticals, Inc. under the ticker symbol BO1 on the Dusseldorf Stock Exchange. Specifically, it highlights data regarding the company's operating cash flow per share. The content is sourced from ICE Data Services, FactSet, American Bankers Association, and Quartr for SEC filings.
BCRX Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an analysis of BioCryst Pharmaceuticals Inc's (BCRX) financial performance, focusing on its revenue breakdown, profitability margins, and a comparison with its competitors. It highlights BCRX's high gross margin of 97.66% and its significant market capitalization. The article also notes the company's operating margin of 64.05% and net margin of 60.47%.
Technical Reactions to BCRX Trends in Macro Strategies
This article analyzes Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) trends using AI models, highlighting weak near-term sentiment despite mid-term strength within a long-term weak bias. It provides distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss points. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.
12 new BioCryst hires receive stock awards tied to 157,300 shares
BioCryst Pharmaceuticals announced that it granted inducement equity awards to 12 newly hired employees on April 1, 2026, including 33,950 stock options and 123,350 restricted stock units (RSUs). These awards, made under Nasdaq Listing Rule 5635(c)(4), have an exercise price of $9.38 per share for options and vest in four equal annual installments. The grants aim to attract new talent and align their interests with the company's growth, especially following strong 2025 financial results.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. announced incentive grants to 12 new employees, including stock options to purchase 33,950 shares and restricted stock units (RSUs) covering 123,350 shares as of April 1, 2026. These grants, made under Nasdaq Listing Rule 5635(c)(4), will vest over four equal annual installments, subject to continued employment, and are intended to serve as material inducements for their employment. The stock options have an exercise price of $9.38 per share and a 10-year term.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. announced that its compensation committee granted stock options and restricted stock units (RSUs) to 12 new employees as inducements for their employment. These grants, totaling 33,950 stock options and 123,350 RSUs, were made on April 1, 2026, with an option exercise price of $9.38 per share, and will vest in four equal annual installments. This action complies with Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals Stock: Navigating Biotech Innovation and Investor Opportunities in Rare Disease Treatments
BioCryst Pharmaceuticals (BCRX) is presented as a compelling investment for North American investors, leading in oral antiviral therapies for rare diseases with strong analyst support and an expanding commercial pipeline. The company's flagship product, ORLADEYO, addresses hereditary angioedema, and its business model focuses on developing small-molecule drugs for unmet needs in immunology and infectious diseases. While the investment carries inherent biotech risks, BioCryst's financial health, growth drivers, and market position in the rare disease sector offer significant upside potential.
BCRX Should I Buy
BioCryst Pharmaceuticals Inc (BCRX) is recommended as a good buy for long-term beginner investors due to strong growth potential, positive analyst ratings, and a bullish technical setup. Despite recent profitability challenges reflected in declining net income and EPS, the company's revenue growth, particularly from Orladeyo's performance, and strategic acquisitions like Astria Therapeutics position it for future success. Analysts, including Wedbush and Evercore ISI, have raised price targets, forecasting a significant rise in BCRX stock price.
Vanguard amends Schedule 13G — BioCryst (BCRX) ownership shown as 0
The Vanguard Group filed an amended Schedule 13G for BioCryst Pharmaceuticals (BCRX), reporting 0 shares beneficially owned and 0% ownership. This change is due to an internal realignment within Vanguard, where certain subsidiaries will now report their holdings separately, in accordance with SEC guidance. The filing clarifies that this amendment does not indicate a sale of shares but rather a disaggregation of reporting.
Does BioCryst Pharmaceuticals (BCRX) Still Offer Value After Recent Share Price Strength?
BioCryst Pharmaceuticals (BCRX) has seen recent share price strength, but a Simply Wall St analysis suggests it may still be undervalued. A Discounted Cash Flow (DCF) model indicates an 87.9% discount to its intrinsic estimate, while its P/E ratio of 8.93x is below industry and peer averages, suggesting it's inexpensive based on its earnings profile. The article encourages investors to consider various "Narratives" or outlooks for the company's future performance.
Does BioCryst Pharmaceuticals (BCRX) Still Offer Value After Recent Share Price Strength?
BioCryst Pharmaceuticals (BCRX) has seen recent share price strength, with a 25.3% year-to-date return. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 87.9% compared to its estimated intrinsic value of $77.96 per share. The company's current P/E ratio of 8.93x is also below both the industry and its peer group averages, further indicating potential undervaluation when considering its earnings growth profile and other fundamentals.
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $13
RBC Capital has reiterated its Buy rating on BioCryst Pharmaceuticals (BCRX.US), maintaining its target price at $13. This indicates a continued positive outlook on the company's stock performance and valuation. The firm's decision suggests confidence in BioCryst's prospects.
Major Insider Move at BioCryst Shakes Up Investor Buzz
BioCryst Pharmaceuticals director Theresa Heggie recently sold 49,933 shares of BioCryst stock for $504,822. This insider move comes as analysts, like Wedbush, are lifting price expectations based on reaffirmed 2026 revenue targets and pipeline progress. TipRanks’ AI Analyst, Spark, rates BCRX as an Outperform due to a sharp financial turnaround and supportive valuation, despite balance-sheet risks.
Insider Sell: Theresa Heggie Sells 49,933 Shares of BioCryst Pha
Theresa Heggie, a Director at BioCryst Pharmaceuticals Inc (BCRX), sold 49,933 shares of the company on March 20, 2026, for a total of approximately $504,926. Following this transaction, she now owns 65,352 shares. The company's stock is considered "Significantly Undervalued" based on its GF Value of $13.96, despite the recent insider selling activity.
Option exercise and sale by BioCryst (BCRX) director Theresa Heggie
BioCryst Pharmaceuticals Inc. director Theresa Heggie exercised stock options for 49,933 shares at $6.30 per share and subsequently sold all of them in the open market at a weighted average price of $10.11 per share on March 20, 2026. After these transactions, she directly holds 65,352 shares of Common Stock. This action aligns with a Rule 10b5-1(c) plan for purchasing or selling equity securities.
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today?
BioCryst Pharmaceuticals (BCRX) stock surged over 10% in after-hours trading, driven by speculation of a potential acquisition by a large U.S. biopharma company, which intensified retail investor sentiment. This buzz follows a "Betaville" alert and increased trading volumes, though some investors remain skeptical given BioCryst's history as an acquirer. The company's growth is primarily fueled by its drug Orladeyo, which generated significant revenue and operating profit last year.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
BioCryst Pharmaceuticals (NASDAQ:BCRX) has received a "Moderate Buy" consensus recommendation from thirteen analysts, with an average 12-month price target of $19.64. The company recently reported strong quarterly earnings, beating estimates with $1.12 EPS and $163.3M in revenue, marking a 209% year-over-year increase. Insider activity includes a significant share sale by director Alane P. Barnes, though insiders still collectively own 5.10% of the stock.
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today?
BioCryst Pharmaceuticals (BCRX) stock surged over 10% in after-hours trading, driven by renewed speculation of a potential takeover by a U.S.-based biopharma company with a market cap exceeding $15 billion. This surge reflects retail investor bullishness and high trading volumes, although some analysts remain skeptical, pointing to BioCryst's history as an acquirer and its strong revenue growth from Orladeyo. The company's CEO, Charlie Gayer, highlighted Orladeyo's market differentiation and indicated that the broader portfolio is expected to grow at mid-teens in revenue well into the 2030s.
Trading the Move, Not the Narrative: (BCRX) Edition
This article provides an AI-driven analysis for Biocryst Pharmaceuticals Inc. (BCRX), highlighting a strong near and mid-term sentiment but a weak long-term outlook. It presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels based on multi-timeframe signal analysis. The report identifies price positioning signals, support, and resistance levels to guide trading decisions.
BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz
BioCryst Pharmaceuticals Inc (BCRX) saw its share prices rise by 7.10% on Thursday, reportedly due to rumors of an acquisition by a large-cap US biopharmaceutical company. The report, which first appeared on a deals website, suggests a US pharmaceutical giant is targeting BioCryst, though the company has not yet confirmed or denied the information. This rally follows BioCryst's strong financial performance in 2025, during which it reported a net income of $263.86 million, a significant turnaround from a net loss in the previous year.
[144] BIOCRYST PHARMACEUTICALS INC SEC Filing
This article reports on a Form 144 SEC filing by BioCryst Pharmaceuticals Inc. (BCRX). The filing details a proposed sale of securities, including information about the issuer, the securities to be sold, and the acquisition details of those securities. It indicates that 49,933 shares will be sold with an aggregate market value of $504,620.17 on March 20, 2026.
BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) saw its share prices rise by 7.10% following rumors of an acquisition by a large-cap US biopharmaceutical company. The company, which specializes in medicines for rare diseases like hereditary angioedema (HAE), recently reported strong earnings for 2025, including a significant swing to net income and a 94% increase in total revenues. BioCryst has yet to confirm or deny the acquisition reports.
BioCryst (BCRX) soars 13% on acquisition buzz
BioCryst Pharmaceuticals (BCRX) experienced a significant 13% surge in its stock price, driven by market speculation and rumors of a potential acquisition. This sudden increase highlights investor reaction to the possibility of the company being acquired, reflecting confidence or strategic interest in its valuation or pipeline.
Is It Time To Reconsider BioCryst Pharmaceuticals (BCRX) After Recent Share Price Strength
BioCryst Pharmaceuticals (BCRX) has seen recent share price strength, with returns of 5.3% over 7 days and 36.2% over 30 days. According to a Discounted Cash Flow (DCF) analysis, the stock appears to be significantly undervalued by 88.0%, with an estimated intrinsic value of US$76.91 per share compared to its recent price of US$9.21. The company's P/E ratio of 8.75x is also well below the industry average, further suggesting it may be undervalued.
BioCryst (BCRX) chief legal officer Barnes sells $1.37m in shares
BioCryst Pharmaceuticals Inc.'s Chief Legal Officer, Alane P. Barnes, sold 150,000 shares of common stock for $1.37 million on March 16, 2026, while also exercising options to acquire an equal number of shares. This transaction was part of a pre-arranged plan and comes after BioCryst reported strong fourth-quarter 2025 earnings, significantly beating Wall Street expectations in both EPS and revenue due to robust sales of its product Orladeyo.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $1,372,500.00 in Stock
BioCryst Pharmaceuticals (NASDAQ:BCRX) insider Alane Barnes sold 150,000 shares of the company's stock for $1,372,500.00 on March 16th, reducing her stake by over 27%. The sale occurred after BioCryst reported strong quarterly earnings, significantly exceeding analyst expectations, and the company currently holds a "Moderate Buy" consensus rating from analysts.
BioCryst (BCRX) CLO sells 150K shares after option exercise
BioCryst Pharmaceuticals' Chief Legal Officer, Alane P. Barnes, exercised stock options for 150,000 shares at $5.51 per share and subsequently sold all 150,000 shares at a weighted average price of $9.15 on March 16, 2026. This transaction was pre-arranged under a Rule 10b5-1 trading plan adopted in August 2025. Following these actions, Barnes directly holds 400,703 shares of BioCryst common stock.
Is It Time To Reconsider BioCryst Pharmaceuticals (BCRX) After Recent Share Price Strength
BioCryst Pharmaceuticals (BCRX) has seen recent share price strength but appears significantly undervalued based on Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) analyses. The DCF model suggests an 88% undervaluation, while its P/E ratio is well below industry averages, indicating lower market expectations than warranted. The article encourages investors to consider these valuation methods and explore different narratives impacting its fair value.
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Its Profitability And Revenue Turnaround
BioCryst Pharmaceuticals (BCRX) has seen a significant turnaround with its Q4 2025 revenue and net income, leading to recent short-term share price gains. Despite a tough five-year performance, the company's profitability has renewed interest, with a popular narrative suggesting it is 58.2% undervalued with a fair value of $20.50 per share. This valuation hinges on the continued success of ORLADEYO and efficient pipeline development.
Form 144 resale notice lists 150,000 shares (NASDAQ: BCRX)
A Form 144 notice filed by BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) on March 16, 2026, indicates that 150,000 shares of common stock are listed for sale under Rule 144. The filing specifies an option grant date of February 27, 2017, and cash as the consideration method, with Fidelity Brokerage Services LLC named as the broker. It also records a previous sale by Alane Barnes of 21,773 shares on December 22, 2025.
BioCryst (BCRX) Soars 13% on Acquisition Buzz
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) experienced a 13.14% surge in its stock price due to rumors of an impending acquisition by a large-cap biopharmaceutical company. The company recently reported strong financial results for 2025, including a significant swing to net income and a 94% increase in total revenues, partly driven by the sale of its European Orladeyo business. While the acquisition rumors remain unconfirmed, the positive financial performance underpins investor interest.
BioCryst (BCRX) Soars 13% on Acquisition Buzz
BioCryst Pharmaceuticals Inc (BCRX) experienced a 13.14% surge in its stock price due to rumors of an impending acquisition by a large-cap biopharmaceutical company. The company recently reported strong financial performance in 2025, swinging from a net loss to a net income and significantly increasing its total revenues through growth and the sale of its European Orladeyo business. BioCryst has not yet confirmed or denied the acquisition reports.
5 Stocks Worth Watching Right Now
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) saw its stock jump on rumors of a potential acquisition by a large-cap biopharmaceutical company. The global biotechnology company, focused on rare diseases, recently reported strong earnings for 2025, swinging to a net income of $263.86 million, and a significant increase in total revenues, partly due to the sale of its European Orladeyo business.
BioCryst Pharmaceuticals jumps as investors revisit profitable 2025 results, upbeat HAE pipeline data, and potential short-covering dynamics
BioCryst Pharmaceuticals (BCRX) saw a 13.7% stock jump, attributed to a positive momentum from its late-February business update. Key factors include the company's first profitable year in 2025 with $602 million ORLADEYO net revenue, maintained 2026 revenue guidance, and promising long-term data for its HAE prophylaxis drug, navenibart. The elevated short interest in the stock likely amplified the upside move due to short covering.
BioCryst Pharmaceuticals Stock Jumps 13.8%
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) surged 13.8% after the biotech company announced positive news regarding its drug pipeline. Investors reacted to developments in its experimental drugs, including Orladeyo, an approved treatment for hereditary angioedema (HAE), and other drug candidates. This jump indicates growing investor confidence in BioCryst's potential to bring new treatments to market and generate revenue, despite facing challenges as a small-cap player in a competitive industry.
BioCryst Pharmaceuticals Sees Profitable Quarter Amid Strategic Moves
BioCryst Pharmaceuticals saw its stock rise by 11.3% after reporting a profitable quarter with an EPS of $1.12 and revenue of $406.6M, driven by strong Orladeyo sales and the acquisition of Astria Therapeutics. Analysts from Evercore ISI and Wedbush have reinstated or raised price targets, reflecting strong confidence in the company's strategic growth and pipeline potential. This performance signals a transition to sustainable profitability, according to market observers.
BioCryst Stock Surges After Strong Q4 Earnings and Astria Acquisition
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) stock surged by 9.91% following a positive Q4 earnings report that exceeded expectations, with EPS rising to $1.12 and revenue tripling to $406.6M. The company's acquisition of Astria Therapeutics further strengthens its position in the hereditary angioedema (HAE) market, contributing to an optimistic outlook and analysts raising price targets. BioCryst forecasts total revenue between $635M and $660M for fiscal year 2026, largely driven by its flagship therapy ORLADEYO.
BioCryst Pharmaceuticals (BCRX) Surges 15% Amid Takeover Specula
BioCryst Pharmaceuticals (BCRX) shares surged 15% following rumors of a potential acquisition by a larger U.S.-based biopharma company. The company also reported a significant earnings beat with a GAAP EPS of $1.12 and strong revenue, supported by a healthy Piotroski F-Score, although its negative equity position and insider selling warrant investor attention. Its market capitalization of approximately $2 billion makes it an attractive target, operating in the specialized oral treatments for rare diseases sector.
Avoro Capital Advisors LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX
Avoro Capital Advisors LLC significantly reduced its stake in BioCryst Pharmaceuticals (BCRX) by 72.2% in the third quarter, selling 3.25 million shares. Despite this reduction, other institutional investors like Arrowstreet Capital and Vanguard Group increased their holdings, leading to an overall institutional ownership of 85.88%. BioCryst recently reported strong quarterly earnings, surpassing analyst expectations, and maintains a "Moderate Buy" consensus rating with a target price of $19.64.
BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush
Wedbush analyst Laura Chico raised the price target for BioCryst Pharmaceuticals Inc. (BCRX) to $22 from $21, maintaining an Outperform rating. This follows the company's strong fourth-quarter results, full-year profitability in 2025, and the acquisition of Astria Therapeutics, which strengthens its hereditary angioedema portfolio. BioCryst's management affirmed its FY26 guidance and growth trajectory.
BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) recently had its price target raised by Wedbush analyst Laura Chico from $21 to $22, with an Outperform rating maintained. This adjustment followed the company's strong fourth-quarter results, which saw a significant increase in revenue and EPS. BioCryst achieved full-year profitability for the first time, bolstered by robust commercial execution and the acquisition of Astria Therapeutics, strengthening its hereditary angioedema portfolio.
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Knott David M Jr
Knott David M Jr significantly reduced its stake in BioCryst Pharmaceuticals (NASDAQ:BCRX) by 90.2% in Q3, selling over 300,000 shares. Despite this, BioCryst exceeded Q4 earnings expectations with EPS of $1.12 and revenue up 209.1% year-over-year. Institutional ownership remains high at 85.88% with several large funds increasing their positions, and analysts maintain a "Moderate Buy" rating with an average price target of $19.64.
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by GW&K Investment Management LLC
GW&K Investment Management LLC reduced its stake in BioCryst Pharmaceuticals (NASDAQ:BCRX) by 16.2% in the third quarter, selling 425,772 shares while still holding 2,197,765 shares valued at $16.68 million. Additionally, insider Alane P. Barnes sold 21,773 shares, decreasing her ownership by 5.18%. Despite these sales, BioCryst reported strong financials, beating EPS and revenue expectations with a 209.1% year-over-year revenue increase.
BioCryst Pharmaceuticals Conference: Profitability Pivot, ORLADEYO Growth, Navenibart Phase 3 Timeline
BioCryst Pharmaceuticals recently discussed its transition to profitability with $601 million in revenue and $214 million in non-GAAP operating profit last year, alongside 2026 guidance predicting up to 13% growth. The company reported strong performance for its HAE drug ORLADEYO, including high patient retention and expansion of its prescriber base, and launched pediatric pellets. Additionally, BioCryst outlined the Phase 3 timeline for its acquired asset navenibart, with an FDA filing possibly by the end of next year, and provided updates on its Netherton syndrome program.
BioCryst Pharmaceuticals Hits Day High with Strong 10.76% Intraday Surge
BioCryst Pharmaceuticals, Inc. experienced a 10.76% stock surge on February 27, 2026, reaching an intraday high of $8.83, and has seen notable increases over the past week (17.45%) and month (29.44%). Despite strong operating profit growth of 198.2% and high institutional holdings, the company faces challenges such as a negative book value and a weak EBIT to interest ratio. Overall, BioCryst is navigating a complex financial landscape with short-term gains but underperformed the S&P 500 over the past year.
